HBK Sorce Advisory’s Crescent Biopharma CBIO Stock Holding History

HBK Sorce Advisory’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-117	Closed	-$2.92K	–	606
2024 Q4	$2.92K	Buy	+117	New	+$3.19K	﹤0.01%	578

Other funds holding CBIO

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

HBK Sorce Advisory's CBIO Position: Q1 2025 in Review

HBK Sorce Advisory sold out of Crescent Biopharma (CBIO) in Q1 2025, closing a stake of 117 shares — an estimated $2.92K sold.

HBK Sorce Advisory first reported a position in CBIO in Q4 2024 and held it in 1 quarter. The position peaked at $2.92K in Q4 2024. 35 funds tracked by Wall St. Rank hold CBIO as of Q1 2025.

HBK Sorce Advisory reported no remaining Crescent Biopharma position as of Q1 2025 after selling out during the quarter.
HBK Sorce Advisory sold 117 Crescent Biopharma shares in Q1 2025, an estimated $2.92K.
HBK Sorce Advisory first reported a position in Crescent Biopharma in Q4 2024 and held it in 1 quarter.
HBK Sorce Advisory's Crescent Biopharma position peaked at $2.92K in Q4 2024.
35 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2025.

Based on HBK Sorce Advisory's 13F filing for Q1 2025, filed 23 Apr 2025.